UNLEASH THE POTENTIAL OF RNA-LNPs TOGETHER
Latest News
Cytiva, now including Precision NanoSystems, is a global leader in technologies, solutions and services for the development of non-viral delivery of genomic medicines, including mRNA vaccines and therapeutics.
Infectious diseases & oncology
Population-based to individualized
Focus on rare diseases
Population-based to individualized
Focus on oncology
Autologous & allogeneic
The proprietary NxGen microfluidic mixer enables the reproducible scale-up of mRNA lipid nanoparticles by preserving the critical conditions at the point of formulation.
-
The scalability and reproducibility of PNI’s NanoAssemblr platform allowed us to move into GMP manufacturing with greater control over the process and increased precision in the final product compared to our previous macromixing process, allowing acceleration of our time to commercialization.
David Evans, PhD
Chief Scientific Officer
Sirnaomics -
PNI is globally renowned for their NanoAssembr suite of products that enable high quality, consistent nanoparticle formation and seamless scale up from the laboratory to GMP manufacturing for the clinic. Using their GMP System will let us meet the challenge of producing our pan-coronavirus DNA vacci...
Read More
John Lewis, PhD
Chief Executive Officer
Entos -
Our government is bringing back the vaccine manufacturing capacity that Canadians expect and need. These investments will help to ensure that Canada has modern, flexible vaccine manufacturing capabilities now and in the future. With the investments announced today, our government is helping Canadian...
Read More
Honourable François-Philippe Champagne
Minister of Innovation, Science and Industry
Government of Canada -
Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's NanoAssemblr GMP System and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture ...
Read More
Kristin Defife, PhD
Vice President and Head of US Operations
Ajinomoto Bio-Pharma Services -
Of particular note is LM03PE which had IgG levels of almost 108 ng/mL. We've never seen antibody levels this high.
Comments on PNI's proprietary RNA-LNP formulations eliciting a strong immune response in an influenza challenge study
Anna Blakney, PhD
Marie Skłodowska-Curie Research Fellow
Imperial College London -
As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr GMP System, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use.
Don Enns
Vice President
Evonik Vancouver Laboratories -
In terms of ease of operation it almost doesn’t compare. The Ignite is really, really smooth. It genuinely takes about half the time to make the same subset of particles when we’re using the same machines (NABT and Ignite). It really does feel like the benchtop came out, it was out for a few years, ...
Read More
Jay Wroe
Sr. Research Associate
Guide Therapeutics -
eTheRNA used the NanoAssemblr® NxGen technology because we could perform precise tuning of the size of our nanoparticles to target the optimal immunogenicity in vivo.
Bernard Sagaert
Vice President of Manufacturing
eTheRNA -
Our team has been dedicated to developing safe and effective vaccines to fight against the COVID-19 pandemic. Since RNA vaccines are a disruptive technology as they do not require cell culture, utilize synthetic delivery and have a smaller manufacturing footprint, our partnership with PNI to advanc...
Read More
Xuefeng Yu, PhD
Co-founder, Chairman and CEO
CanSinoBIO
